ArticleInvestigative ophthalmology & visual science2009
Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564).
Article in Investigative ophthalmology & visual science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Unveiling molecular insights: in silico exploration of TLR4 antagonist for management of dry eye syndrome.BMJ open ophthalmology · 2024Article
- HSP60-Derived Peptide as an LPS/TLR4 Modulator: AnFrontiers in cardiovascular medicine · 2022Article
- TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection.Frontiers in immunology · 2020Review
- Tunable Enzymatic Synthesis of the Immunomodulator Lipid IVJournal of the American Chemical Society · 2019Article
- Mitogenic lectins from Cephalosporium curvulum (CSL) and Aspergillus oryzae (AOL) mediate host-pathogen interactions leading to mycotic keratitis.Molecular and cellular biochemistry · 2017Article
- CLI-095 decreases atherosclerosis by modulating foam cell formation in apolipoprotein E-deficient mice.Molecular medicine reports · 2016Article
- Challenges of corneal infections.Expert review of ophthalmology · 2016Article
- Review
- CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Dry eye modulates the expression of toll-like receptors on the ocular surface.Experimental eye research · 2015Article
- Inhibition of Corneal Inflammation by the Resolvin E1.Investigative ophthalmology & visual science · 2015Article
- Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling.Molecular medicine (Cambridge, Mass.) · 2015Article
- The use of an IL-1 receptor antagonist peptide to control inflammation in the treatment of corneal limbal epithelial stem cell deficiency.BioMed research international · 2015Article
- The role of toll-like receptor 4 in corneal epithelial wound healing.Investigative ophthalmology & visual science · 2014Article
- Protective role of murine β-defensins 3 and 4 and cathelin-related antimicrobial peptide in Fusarium solani keratitis.Infection and immunity · 2013Article
- Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118).Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2013Article
- Host defense at the ocular surface.International reviews of immunology · 2013Review
- Monosodium Urate and Tumor Necrosis Factor-α Increase Apoptosis in Human Chondrocyte Cultures.Rheumatology (Sunnyvale, Calif.) · 2012Article
- Innate immune regulation of Serratia marcescens-induced corneal inflammation and infection.Investigative ophthalmology & visual science · 2012Article
- Expression of toll-like receptor 4 contributes to corneal inflammation in experimental dry eye disease.Investigative ophthalmology & visual science · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo investigate the role of the TLR4/MD-2 antagonist eritoran tetrasodium in a murine model of contact lens-associated corneal infiltrates.
methodsC57BL/6 mouse corneas were abraded and treated with eritoran tetrasodium or placebo, either before or after stimulation with either LPS, the TLR2 ligand Pam(3)Cys, or antibiotic-killed Pseudomonas aeruginosa. A 2-mm punch from a silicon hydrogel contact lens was used to cover the corneal surface throughout the inhibition and stimulation period. Corneal infiltrates were detected by in vivo confocal microscopy and by immunohistochemistry for neutrophils. The effect of eritoran tetrasodium on stimulated human corneal epithelial cells (HCECs), macrophages, and neutrophils was also assessed.
resultsEritoran tetrasodium significantly inhibited CXC chemokine production in the cornea and development of corneal infiltrates, specifically neutrophils, in response to stimulation with LPS (TLR4), but not Pam(3)Cys (TLR2). When the antagonist was applied after LPS stimulation, neutrophil infiltration was also inhibited, although a higher concentration was needed. Furthermore, IL-8 production by TLR4- but not TLR2-stimulated HCECs, macrophages and neutrophils was also significantly reduced. Corneal inflammation induced by P. aeruginosa in the presence of tobramycin was found to be dependent on expression of TLR4 and MD-2 and is inhibited by eritoran tetrasodium.
conclusionsEritoran tetrasodium is a highly effective antagonist of TLR4/MD-2-dependent corneal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.